Merck/Kyorin Phase III Dual PPAR Agonist On First-In-Class Path For Diabetes
Executive Summary
Merck/Kyorin's dual peroxisome proliferator-activated receptor agonist MK-0767, a new antidiabetic in Phase III, appears to be winning the development race for first market entrant in its class
You may also be interested in...
Merck Gets Second Chance On Dual PPAR: Will Develop Bristol’s Muraglitazar
Merck's co-development agreement for Bristol Myers-Squibb's Phase III muraglitazar gives the company a second chance to market a dual PPAR agonist
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011